{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:56:54Z","timestamp":1762981014366},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Recent therapeutic advancements have incorporated immune checkpoint inhibitors (ICIs) into the management of metastatic renal cell carcinoma. Pivotal phase III trials have resulted in Food and Drug Administration approval for anti\u2013programmed death 1\/programmed death ligand 1 ICIs, either in combination with anti\u2013cytotoxic T-lymphocyte antigen 4 ICIs or with vascular endothelial growth factor\u2013directed targeted therapies, as standard-of-care frontline regimens. Immune checkpoint inhibitors offer improved clinical outcomes when compared to previous treatment options. However, these agents also present unique toxicity profiles collectively referred to as immune-related adverse events. Common immune-related adverse events include colitis, hepatitis, dermatitis, and thyroiditis. Rare toxicities, such as myocarditis and pneumonitis, have the potential for causing severe harm. Herein, we provide a case-based discussion of how to identify, grade, and manage irAEs in metastatic renal cell carcinoma.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000473","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:32:38Z","timestamp":1600302758000},"page":"432-440","source":"Crossref","is-referenced-by-count":4,"title":["Immune Related Adverse Events"],"prefix":"10.1097","volume":"26","author":[{"given":"Zeynep B.","family":"Zengin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Chehrazi-Raffle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Meza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasnoor","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"261","DOI":"10.21037\/atm.2016.04.01","article-title":"Harnessing the immune system to improve cancer therapy","volume":"4","year":"2016","journal-title":"Ann Transl Med"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","year":"2018","journal-title":"J Immunother Cancer"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor\u2013induced toxic effects with shared cancer and tissue antigens in non\u2013small cell lung cancer","volume":"5","year":"2019","journal-title":"JAMA Oncol"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with Pembrolizumab","volume":"152","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"15_suppl","key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/jco.2011.29.15_suppl.2505","article-title":"Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade\u2013induced colitis","volume":"7","year":"2016","journal-title":"Nat Commun"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40261-018-0735-0","article-title":"Adverse event profiles of anti\u2013CTLA-4 and anti\u2013PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS","volume":"39","year":"2019","journal-title":"Clin Drug Investig"},{"key":"bib15-20230924","first-page":"230ra45","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte\u2013associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","year":"2016","journal-title":"Am J Pathol"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non\u2013small-cell lung cancer","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib19-20230924","first-page":"1671","article-title":"Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials","volume":"10, 10","year":"2019","journal-title":"Front Pharmacol"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","year":"2019","journal-title":"JAMA Oncol"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti\u2013CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","year":"2015","journal-title":"BMC Med"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4 suppl","key":"bib25-20230924","first-page":"iv119","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","year":"2017","journal-title":"J Immunother Cancer"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"bib30-20230924","first-page":"13","article-title":"Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management","volume":"38","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","year":"2017","journal-title":"Int J Cancer"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","article-title":"Ipilimumab associated hepatitis: imaging and clinicopathologic findings","volume":"31","year":"2013","journal-title":"Invest New Drugs"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1200\/JCO.2010.32.2206","article-title":"Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","article-title":"Anti\u2013PD-1\u2013induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report","volume":"67","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials","volume":"119","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte\u2013associated antigen 4","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/MCG.0b013e31828f1d51","article-title":"Ipilimumab-induced perforating colitis","volume":"47","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"rju010","DOI":"10.1093\/jscr\/rju010","article-title":"Ipilimumab-induced colonic perforation","volume":"2014","year":"2014","journal-title":"J Surg Case Rep"},{"key":"bib40-20230924","first-page":"3406437","article-title":"Anti\u2013PD-1 therapy\u2013associated perforating colitis","volume":"2018","year":"2018","journal-title":"Case Rep Gastrointest Med"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti\u2013CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","year":"2016","journal-title":"J Crohns Colitis"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor\u2013induced colitis","volume":"6","year":"2018","journal-title":"J Immunother Cancer"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2326-6066.CIR-16-0302","article-title":"Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients","volume":"5","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"W468","DOI":"10.2214\/AJR.12.9751","article-title":"Ipilimumab-associated colitis: CT findings","volume":"200","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor\u2013related colitis","volume":"24","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3748\/wjg.v23.i11.2023","article-title":"Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis","volume":"23","year":"2017","journal-title":"World J Gastroenterol"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/jclinpath-2018-205143","article-title":"Immune checkpoint inhibitor\u2013induced gastrointestinal and hepatic injury: pathologists' perspective","volume":"71","year":"2018","journal-title":"J Clin Pathol"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ibd\/izy240","article-title":"Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity?","volume":"25","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab treatment for immune checkpoint inhibitor\u2013induced enterocolitis","volume":"66","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor\u2013associated colitis","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.14309\/ajg.0000000000000282","article-title":"Immunotherapy-associated pseudomembranous colitis","volume":"114","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","year":"2016","journal-title":"Kidney Int"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","year":"2019","journal-title":"J Immunother Cancer"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","year":"2017","journal-title":"Eur J Cancer"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","year":"2017","journal-title":"Oncologist"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Rapid increase in reporting of fatal immune checkpoint inhibitor associated myocarditis","volume":"391","year":"2018","journal-title":"Lancet"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","year":"2019","journal-title":"J Immunother Cancer"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","year":"2016","journal-title":"Eur J Cancer"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor\u2013induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","year":"2019","journal-title":"Horm Metab Res"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies","volume":"13","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti\u2013programmed death-1\/programmed death ligand 1 therapy","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor\u2013related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","year":"2016","journal-title":"JAMA Oncol"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non\u2013small cell lung cancer","volume":"152","year":"2017","journal-title":"Chest"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3389\/fphar.2018.01430","article-title":"The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis","volume":"9","year":"2018","journal-title":"Front Pharmacol"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-030-02505-2_6","article-title":"Immune-related adverse events: pneumonitis","volume":"995","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","year":"2018","journal-title":"Autoimmun Rev"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor\u2013related myositis and myocarditis in patients with cancer","volume":"91","year":"2018","journal-title":"Neurology"},{"key":"bib74-20230924","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor\u2013associated myocarditis","volume":"23","year":"2018","journal-title":"Oncologist"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","article-title":"Ocular and orbital side-effects of checkpoint inhibitors: a review article","volume":"28","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and clinical patterns of ocular complications associated with anti\u2013PD-1\/PD-L1 anticancer immunotherapy","volume":"202","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","year":"2019","journal-title":"Oncologist"},{"key":"bib79-20230924","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti\u2013PD-1 or anti\u2013PD-L1 immunotherapy: a descriptive observational study","volume":"6","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:25:12Z","timestamp":1695533112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000473"}},"subtitle":["Classification and Management Approaches in Advanced Kidney Cancer"],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000473","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}